Intrauterine Antibiotic Infusion in Treating Chronic Endometritis and Restoring Reproductive Dynamics
NCT ID: NCT04447625
Last Updated: 2020-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
80 participants
INTERVENTIONAL
2017-03-01
2020-01-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Εffectiveness of Intrauterine Antibiotic Administration for Treatment of Chronic Endometritis
NCT05205993
Diagnostics of Chronic Endometritis in Infertility
NCT05946655
The Role of Novel Organisms in Acute Endometritis
NCT01236131
anti_endometrial Antibodies in Endometriosis
NCT05851352
Development of a Microbiome Non-invasive Diagnosis Tool
NCT03330444
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CE patients receiving OAA
Patients diagnosed with CE receiving the gold standard treatment of oral antibiotic administration (OAA)
Oral antibiotic administration
per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
CE patients receiving OAA and IAI
Patients diagnosed with CE receiving a combination of the gold standard treatment of oral antibiotic administration (OAA) and intrauterine antibiotic infusion (IAI)
Oral antibiotic administration
per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
Intrauterine antibiotic infusion
intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral antibiotic administration
per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
Intrauterine antibiotic infusion
intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Recurrent Pregnancy Loss (RPL) or Recurrent Implantation Failure (RIF)
* No previous live birth
* FSH and LH levels -evaluated on day 2 of the menstrual cycle- \<12 IU/ml
* AMH levels \>1.1ng/ml
* Progesterone levels -evaluated on day 21 of the menstrual cycle- \> 2 and \<25 ng/ml
* 18.5\<BMI\<29.9
* 18\<Patients' age\<40
Exclusion Criteria
* Current or previous cancer diagnosis
* Auto-immune, genetic or reproductive disorders
* Reproductive history of pregnancy loss due to genetic abnormalities
* Male factor infertility diagnosis
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genesis Athens Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Human Reproduction LTD
Athens, Holargos, Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.